Regen BioPharma, Inc.
RGBP · OTC
9/30/2025 | 9/30/2024 | 9/30/2023 | 9/30/2022 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $0 | $0 | $0 | $0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -46.5% | 0% | 0.4% | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | 28.9% | 100% | 100% | 78.8% |
| EBITDA | -$0 | -$0 | $0 | $0 |
| % Margin | -267.5% | -176.7% | 1,318.5% | 1,270.8% |
| Net Income | -$0 | -$0 | $0 | $0 |
| % Margin | -1,007% | -282.4% | 432.9% | 945.6% |
| EPS Diluted | -0.05 | -0.16 | 0.14 | 0.36 |
| % Growth | 68.8% | -214.3% | -61.1% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | $0 | $0 | -$0 | $0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |